Abaloparatide
Also known as: Abaloparatide acetate, abaloparatide‑sen, ABL, ABP‑125, BA058, PTHrP analogue, Tymlos
Source Abaloparatide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Abaloparatide is a synthetic 34‑amino‑acid peptide analogue of human parathyroid hormone‑related peptide (PTHrP) used as a daily subcutaneous injection to increase bone mineral density and reduce fracture risk in postmenopausal women with osteoporosis.
Mechanism of Action
Selective activation of the PTH1 receptor, stimulating bone formation while minimizing bone resorption
Routes of Administration
Goals & Uses
- Treatment of male osteoporosisBone HealthModerate
- Reduction of vertebral fracture riskBone HealthHigh
- Increase in bone mineral density (BMD)Bone HealthHigh
- Reduce vertebral fracture riskEfficacyHigh
- Anabolic bone therapy before antiresorptive treatmentBone HealthModerate
- Increase bone mineral densityBone HealthHigh
- Reduction of nonvertebral fracture riskBone HealthHigh
Contraindications
- Hypersensitivity to abaloparatide or any excipientAllergyHigh
- Prior external beam or implant radiation therapy to the skeletonRadiation HistoryHigh
- Pediatric patients or open epiphysesAge/developmentalHigh
- HypercalcemiaMetabolic DisorderHigh
- Bone metastases or skeletal malignancyOncologyHigh
- Paget's disease of boneBone DisorderHigh
- Prior radiation therapy to the skeletonSkeletalModerate
- Paget disease of boneSkeletalModerate
- Metabolic bone diseases other than osteoporosis (e.g., Paget disease, osteitis deformans)Bone DiseaseModerate
Adverse Effects
- HypercalcemiaMetabolicCommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- HypercalciuriaMetabolicCommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Injection‑site reactionsLocalCommon
- OsteosarcomaOncologyRare
- DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
- Orthostatic hypotension/dizzinessCardiovascularCommon
Drug Interactions
- BisphosphonatesModerate
- Antiresorptive agents (bisphosphonates, denosumab)Low
- Calcium supplements / Vitamin DLow
- Calcium supplementsModerate
- Thiazide diureticsModerate
Population Constraints
- PregnancyReproductive SafetyAbsolute
- Pediatric patientsAgeAbsolute
- LactationReproductiveRelative
- Prior osteosarcoma or high-risk bone conditionsOncologyAbsolute
- Pregnant or breastfeeding womenReproductiveAbsolute
- Renal impairment (severe, CrCl <30 mL/min)RenalRelative
- Severe renal impairment (eGFR <30 mL/min)RenalRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization as of 2024
- United StatesApprovedApproved: Postmenopausal osteoporosisApproved 2017; brand name Tymlos
- United KingdomUnapprovedFollows EU status
Approved by the US FDA in 2017 (brand name Tymlos) for osteoporosis; not approved in the EU as of 2024.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Abaloparatide?
Abaloparatide is a synthetic 34‑amino‑acid peptide analogue of human parathyroid hormone‑related peptide (PTHrP) used as a daily subcutaneous injection to increase bone mineral density and reduce fracture risk in postmenopausal women with osteoporosis.
What is Abaloparatide used for?
Abaloparatide is educationally associated with: Treatment of male osteoporosis, Reduction of vertebral fracture risk, Increase in bone mineral density (BMD), Reduce vertebral fracture risk, Anabolic bone therapy before antiresorptive treatment, Increase bone mineral density, Reduction of nonvertebral fracture risk. Educational only — not medical advice.
How is Abaloparatide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Abaloparatide?
Reported adverse effects include: Hypercalcemia, Injection site reactions, Headache, Hypercalciuria, Nausea, Injection‑site reactions, Osteosarcoma, Dizziness, Orthostatic hypotension/dizziness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Abaloparatide?
Recorded contraindications: Hypersensitivity to abaloparatide or any excipient, Prior external beam or implant radiation therapy to the skeleton, Pediatric patients or open epiphyses, Hypercalcemia, Bone metastases or skeletal malignancy, Paget's disease of bone, Prior radiation therapy to the skeleton, Paget disease of bone, Metabolic bone diseases other than osteoporosis (e.g., Paget disease, osteitis deformans). Consult a qualified clinician before use.